Incidence of Metastasis in the Central Nervous System in Advanced Breast Cancer Treated With CDK 4/6 Inhibitors: A Multicenter, Retrospective Study
Abstract Central nervous system (CNS) metastasis remains a major cause of mortality in advanced breast cancer (ABC). While cyclin‐dependent kinase 4/6 inhibitors (CDKIs) combined with endocrine therapy (ET) delay resistance in hormone receptor (HR)‐positive and human epidermal growth factor receptor...
Saved in:
| Main Authors: | Yan‐Ling Wen, Xi‐Wen Bi, Xue‐Wen Zhang, Si‐Fen Wang, Chang Jiang, Li Wang, Yong‐Yi Zhong, Yuan‐Yuan Huang, Jian‐Li Zhao, Qian‐Jun Chen, Cong Xue, Zhong‐Yu Yuan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
by: Sarah Alexandrou, et al.
Published: (2025-08-01) -
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01) -
New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy
by: Wei Dai, et al.
Published: (2025-07-01) -
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement
by: Andrew J. Sunderland, et al.
Published: (2020-01-01) -
The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)